Totus Medicines and Lilly Form Strategic Research Partnership

Totus Medicines, a pioneer in small molecule drug discovery and development, has announced a significant collaboration with Eli Lilly and Company. This partnership aims to discover small molecule drug candidates targeting various therapeutic areas using Totus' innovative covalent DNA-encoded libraries and artificial intelligence tools.

Under the agreement, Totus Medicines will deploy its proprietary OmniDEL platform to create high-quality covalent compounds specifically aimed at targets identified by Lilly. Following the identification phase, both companies will have the option to jointly engage in the preclinical and clinical development, as well as the commercialization, of the compounds resulting from this collaboration. Milestone payments will be part of the financial framework of the partnership.

Nassim Usman, Ph.D., the President and CEO of Totus Medicines, expressed excitement about the collaboration. He emphasized that partnering with a globally renowned pharmaceutical company like Lilly highlights the potential and validity of Totus' OmniDEL platform. This technology not only assists in identifying promising small molecule drug candidates for partners but also supports Totus' internal drug development pipeline. Currently, Totus has a covalent PI3Kα inhibitor in Phase 1 clinical trials and an AKT covalent inhibitor in preclinical stages of development.

Totus Medicines is at the forefront of discovering and developing small molecule medicines, utilizing a proprietary technology that combines DNA-encoded covalent libraries with advanced AI and machine learning techniques. This cutting-edge platform allows for the simultaneous screening of billions of drug candidates against multiple targets, which is unprecedented in the field. The result is the identification of drug candidates that are significantly more effective compared to those discovered through traditional methods. Totus' approach also includes targeting molecules that have been historically challenging to drug.

One of the standout projects in Totus' pipeline is TOS-358, a covalent PI3Kα inhibitor currently undergoing Phase 1 clinical trials. Additionally, the company has developed a potent and selective covalent inhibitor of AKT, which is still in the preclinical development phase.

Totus Medicines continues to make strides in the field of small molecule drug discovery by leveraging its innovative platform and strategic collaborations. The partnership with Eli Lilly and Company marks a significant step in the company's mission to develop superior drugs for various therapeutic areas, ultimately aiming to address unmet medical needs and improve patient outcomes.